This company listing is no longer active
46L Stock Overview
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
SeaSpine Holdings Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$8.80 |
52 Week High | US$12.30 |
52 Week Low | US$5.30 |
Beta | 1.3 |
1 Month Change | 29.41% |
3 Month Change | 55.75% |
1 Year Change | -20.00% |
3 Year Change | -33.53% |
5 Year Change | n/a |
Change since IPO | -33.78% |
Recent News & Updates
Recent updates
Shareholder Returns
46L | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 20.5% | -1.8% | 0.8% |
1Y | -20.0% | 5.5% | 6.2% |
Return vs Industry: 46L exceeded the German Medical Equipment industry which returned -29.1% over the past year.
Return vs Market: 46L matched the German Market which returned -20.1% over the past year.
Price Volatility
46L volatility | |
---|---|
46L Average Weekly Movement | 10.5% |
Medical Equipment Industry Average Movement | 4.2% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 46L's share price has been volatile over the past 3 months.
Volatility Over Time: 46L's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 523 | Keith Valentine | https://www.seaspine.com |
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company’s orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures.
SeaSpine Holdings Corporation Fundamentals Summary
46L fundamental statistics | |
---|---|
Market cap | €342.28m |
Earnings (TTM) | -€61.61m |
Revenue (TTM) | €218.33m |
1.6x
P/S Ratio-5.6x
P/E RatioIs 46L overvalued?
See Fair Value and valuation analysisEarnings & Revenue
46L income statement (TTM) | |
---|---|
Revenue | US$229.75m |
Cost of Revenue | US$87.83m |
Gross Profit | US$141.92m |
Other Expenses | US$206.75m |
Earnings | -US$64.84m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.72 |
Gross Margin | 61.77% |
Net Profit Margin | -28.22% |
Debt/Equity Ratio | 9.4% |
How did 46L perform over the long term?
See historical performance and comparison